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Abstract
The hallmark of renal cell carcinoma is its biological characteristic of invading the renal 
vein and/or inferior vena cava (IVC), which occurs in 4–10% of patients. Radical nephrec-
tomy (RN) with tumor thrombectomy is the standard approach for treating such chal-
lenging cases. Except tumor thrombus height, several factors can determine the surgical 
strategy, including the effect of targeted molecular therapy (TMT), invasion of the IVC 
wall, venous occlusion, establishment of collateral circulation, IVC thromboembolism, 
and primary tumor location. The surgical strategy for patients with retrohepatic vena 
cava tumor thrombi depends on the upper extent of the tumor thrombus. In addition, 
the first porta hepatis and hepatic veins are important anatomical boundaries. Based on 
previous studies, the effect of pre-surgical TMT is limited. The safety of IVC venography, 
an imaging modality that can observe congestion of the tumor thrombus and show the 
collateral circulation, has considerably improved. IVC interruption plays an important 
role in tumor thrombectomy for patients with invasion of the venous walls, complete 
occlusion of the vena cava, and the presence of distal thrombus. A series of retrospective 
and prospective studies are needed to be conducted, which will provide our clinical work 
with more powerful reference and basis.
Keywords: renal cell carcinoma, tumor thrombus, targeted molecular therapy, inferior 
vena cava venography, vascular resection, surgical strategy
1. Introduction
The Chinese Cancer Registry Annual Report of 2015 indicates that renal cell carcinoma (RCC) 
represents approximately 2–3% of new cases of malignant tumor in China annually and the 
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trend in the morbidity of RCC has been increasing [1]. The hallmark of RCC is its biologi-
cal characteristic of invading the renal vein and/or inferior vena cava (IVC), which occurs in 
4–10% of patients [2]. Past clinical decision making mostly adopts conservative treatment, in 
terms of high morbidity and mortality rates during this kind of procedures. Radical nephrec-
tomy (RN) with tumor thrombectomy is the standard approach for treating such challenging 
cases [3]. These patients were able to obtain, as literature reported, better long-term survival, 
and the tumor-specific survival rate is in up to 50% [4–7].
With the development of laparoscopy and robotic technology and the accumulation of 
practical experience in surgery, we noted that the height of IVC thrombus could not suf-
ficiently guide the choice of surgical strategy, considering that only the thrombus height 
was assessed. Several factors, such as the effect of neoadjuvant targeted molecular therapy 
(TMT), invasion of the IVC wall, venous occlusion, establishment of collateral circulation, 
IVC thromboembolism, and primary tumor location, can determine the surgical strategy. 
The present comprehensive review describes how those factors influence surgical strategy 
and patient outcomes.
2. Technological innovations and classifications
RCC tends to invade the renal venous system, forming a thrombus that invades the IVC and 
even involving the right atrium [2]. RN with tumor thrombectomy is the standard approach 
for treating such challenging cases. The grading system based on tumor thrombus height 
was created to determine surgical strategies. As early as 1987, the Mayo Clinic had adopted 
the “NEVES grading.” Level I is defined as a tumor thrombus that is <2 cm apart from the 
orificium of the renal vein. Level II is defined as a tumor thrombus extending to the IVC 
>2 cm above the renal vein but below the hepatic veins. Level III is defined as a tumor throm-
bus that extends above the hepatic veins but below the diaphragm. Level IV is defined as a 
tumor thrombus located above the diaphragm. Surgical strategies are varied in correspond-
ing levels. Traction of the liver is required in levels I to II. Turning-up the liver, blocking-up 
vessels located below the diaphragm, and clamping the portal vein are required in levels 
II to III. The establishment of an extracorporeal circulation is necessary in levels III and IV 
[8]. In 2002, the University of Miami divided level III tumor thrombus into four categories 
ulteriorly, which corresponded to diverse surgical strategies [9]. However, the most classic 
guideline is the “5-level classification” of a tumor thrombus, which was proposed by the 
Mayo Clinic in 2004 [10]. Idiographic grading standards and surgical strategies are shown 
in Table 1.
Nevertheless, these grading systems are completely based on the experience of open surgery. 
Since Skinner first reported the open surgery of IVC tumor thrombectomy in 1972 [11], the 
technique of IVC tumor thrombectomy has been improving continuously. Some scholars had 
attempted to accomplish these surgeries with laparoscope in 2002 [12, 13]. In 2011, Abaza 
first reported on robot-assisted IVC tumor thrombus extraction [14]. In recent years, several 
medical centers have investigated the safety and feasibility of robot-assisted laparoscopic 
IVC thrombectomy (RAL-IVCTE) [15–18]. Based on the anatomic characteristics of RCC, we 
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reported the particular steps of robot-assisted surgery and concluded that RAL-IVCTE is 
safe, and different sides require different techniques [18]. Gu and colleagues performed a 
retrospective comparison between open and robotic surgeries in IVC thrombus. The study 
indicated that level I–II IVC tumor thrombectomy performed with robot-assisted surgery 
resulted in better perioperative periodical outcomes and analogous oncological outcomes 
compared with open surgery, marking that such surgery has entered the era of mini-trau-
matic surgery [19].
3. Surgical procedure
3.1. Anesthesia and patient position
After general anesthesia induction and Foley catheter placement, the patients were positioned 
in a left lateral decubitus position with a 60–70° bump (Figure 1A and B). For right RCC, 
R-IVCTE and RN can be both completed with this position. For left RCC, R-IVCTE can be 
completed with this position. After R-IVCTE, the placement of patients was converted to a 
right lateral decubitus position with a 60–70° bump, and left RN was performed.
3.2. Right RN and IVC thrombectomy
The hepatocolic, hepatorenal, and chain ligaments were incised. The liver required to be up-
retracted. The anterior layer of the perirenal fascia was opened, the duodenum was dissected 
and retracted inside, and the IVC was exposed. Full dissection of the IVC, left renal vein, and 
part of the lumbar vein were required at the location of the tumor thrombus (Figure 1C). For 
level II IVC thrombus, the hepatic short vein, and even right central vein of the adrenal gland, 
was also clipped and divided (Figure 1D). Sequential clamping of the caudal IVC, left renal 
vein, and cephalic IVC were performed using vessel loops (Figure 1E). After the vessels were 
clamped, the IVC wall was cut, and the thrombus was removed (Figure 1F). After the IVC 
Tumor 
thrombus level
Definition Surgical strategy
0 Tumor thrombus is limited to the renal vein Radical nephrectomy of renal cell carcinoma
I Tumor thrombus extend into IVC with <2 cm 
above the renal vein
Tumor thrombus could be extruded to renal vein 
and then radical nephrectomy
II Tumor thrombus extends in to IVC >2 cm 
above the renal vein but below the hepatic 
veins
The traction of liver is required; blocking-up the 
section of IVC underneath hepatic vein
III Tumor thrombus which extends above the 
hepatic veins but below diaphragm
The mobilization of the liver; vena-venous bypass 
is required
IV Tumor thrombus is above diaphragm Intraoperative extracorporeal circulation is requisite
IVC = inferior vena cava.
Table 1. The grading standards and surgical strategies tumor thrombus.
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lumen was irrigated with heparinized saline, 5-0 polypropylene suture was used to close the 
IVC (Figure 1G). The tourniquets of the caudal IVC, left renal vein, and cephalic IVC were 
sequentially loosened. In the same position, right RN was completed.
Figure 1. Surgical procedure for robot-assisted laparoscopic inferior vena cava thrombectomy. Patient position and port 
placement is shown, with three assistant ports used. (A and B). The inferior vena cava and left renal vein was exposed 
(C). The hepatic short vein was clipped and divided (D). Sequential clamping caudal IVC, left renal vein, and cephalic 
IVC were performed by vessel loops (E). The thrombus was removed (F). The IVC was closed with 5-0 polypropylene 
suture (G). Ligation and division of the left renal vein for the left RCC (H). Intraoperative IVC interruption in selected 
cases (I). IVC = inferior vena cava; RCC = renal cell carcinoma.
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3.3. Left RN and IVC thrombectomy
The patient position and port placement were the same as those for the right RCC. However, 
we suggest that left renal artery embolization must be performed 1–2 h preoperatively. The 
steps were similar in dissecting the IVC. Subsequently, we ligated and divided the left renal 
vein, which included the thrombus, with Endo-GIA (Figure 1H). The clamping sequence 
was the caudal IVC first, followed by the right renal artery, right renal vein, and cephalic 
IVC. After thrombus removal, the placement of the patients was converted to a right lateral 
decubitus position, with a 60–70°bump, and left RN was performed.
3.4. Surgical technique for retro- or superohepatic IVC thrombus
Recently, the latest research completed by our team investigated the surgical method of 
robot-assisted retro- or superohepatic vena caval tumor thrombectomy and its influence 
factor. We found that the surgical strategy for patients with retrohepatic vena caval tumor 
thrombi depends on the upper extent of the tumor thrombus [20]. In addition, the first porta 
hepatis and hepatic veins are important anatomical boundaries. The surgical technique was 
described as follows. If the retrohepatic thrombus was located inferior to the first porta hepa-
tis (Figure 2A), some short hepatic veins should be ligated, but the liver should not be mobi-
lized. If the retrohepatic thrombus was located between the first porta hepatis and hepatic 
veins (Figure 2B), mobilization of the right lobe of the liver is an important step. For retro-
hepatic thrombus located closer or above the second porta hepatis (liver vein) but below the 
infra-diaphragm (Figure 2C), mobilization both the right and left lobes of the liver can facili-
tate high proximal control of the superohepatic IVC. In addition, the first porta hepatis should 
be clamped. For superohepatic (level IV) thrombus, thoracoscope-assisted open atriotomy 
was performed to cut the atrial part of the thrombus, and vena caval tumor thrombectomy 
was subsequently performed by clamping the superodiaphragm IVC after cardiopulmonary 
bypass was established (Table 2).
Figure 2. The first porta hepatis and hepatic veins are important anatomical boundaries on representative images of 
radiography. The retrohepatic thrombus inferior to the first porta hepatis (A). The retrohepatic thrombus inferior to the 
first porta hepatis (B). The retrohepatic thrombus closer or above the second porta hepatis (liver vein) but blew infra-
diaphragm (C). FPH = first porta hepatis; SPH = second porta hepatis; IVC = inferior vena cava tumor.
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4. Preoperative targeted therapy
Although mini-traumatic surgery has been applied in patients with RCC and tumor throm-
bus, level III and IV tumor thrombus might have lethal complications, including hemorrhage, 
thrombotic shedding, etc. The operative mortality and overall morbidity rates of postopera-
tive complication of patients with tumor thrombus patients have been reported up to 5–10% 
and 38%, respectively [21]. Moreover, as tumor thrombus level advanced, the morbidity of 
perioperative periodical complications is higher accordingly. With regard to patients with 
level III and IV tumor thrombus, surgical strategies usually involve thoracotomy, dealing 
with retro- or superohepatic IVC, and establishing extracorporeal circulation, which can be 
achieved with the assistance of hepatobiliary and cardiovascular surgeons.
With the targeted molecular therapy (TMT) of rising, TMT has been widely acknowledged 
as the most effective treatment for advanced RCC, particularly for patients with metastatic 
RCC. In recent years, targeted drugs have been reported to be applied in preoperative adjunc-
tive therapy for tumor thrombus because of its high success rate in the treatment of advanced 
RCC [22, 23]. The purpose of administering target drugs was to lessen the height of tumor 
thrombus or shrink the primary lesions or metastases, which may enhance the safety and 
feasibility of surgical intervention. The results of some retrospective observations with a 
small sample present diversities [24–26]. After preoperative TMT, 44–76% of the patients’ 
IVC tumor thrombus had shrinkage in different degrees, with tumor thrombus degradation 
averaging approximately 20%. Cost and colleagues reported a retrospective outcome from a 
sample of 25 patients, wherein three patients (12%) had a reduction in the thrombus degrada-
tion, and one patient (4%) had an increase [25]. As a result of first-class evidence deficiency, 
this therapeutic regimen has not been recommended by the guidelines. Thus, further prospec-
tive investigations with a larger number of patients are needed to overcome the limitations.
Location of IVC thrombus Surgical strategy
Retrohepatic but inferior to the FPH 1. Ligating some SHV
2. Retracting but not liver mobilization
Retrohepatic and between the FPH and hepatic veins 1. Ligating more SHV
2. Mobilizing the right lobe of the liver.
3. Not clamping FPH
Retrohepatic and closer (level II) or above (level III)  
the second porta hepatis (liver vein) yet 
infra-diaphragm
1. Mobilizing both the right and left lobes of the liver
2. High proximal control of superohepatic IVC
3. Clamping of the FPH Simultaneously
Superohepatic (level IV) 1. Thoracoscopic atriotomy for cutting atrial part of the 
thrombus
2. Establishing cardiopulmonary bypass
3. Performing IVC tumor thrombectomy after Clamping the 
superodiaphragm IVC
IVC = inferior vena cava; SHV = short hepatic vein; FPH = first porta hepatis.
Table 2. Changes of techniques for robot-assisted retro- or supero-hepatic vena caval tumor thrombectomy in our 
method.
Kidney Cancer6
5. Postoperative targeted therapy in patients without metastasis
For patients with non-metastatic RCC and tumor thrombus, the recurrence rate of the tumor 
is approximately 50% at 3 years preoperatively, despite performing RN [27]. Thus, for these 
patients, only operative treatment may not be sufficient. Adjuvant IL-2/IFN applied in prophase 
postoperatively, chemotherapy, and hormone therapy are all negative for high-recurrence risk 
RCC [28]. Small molecules targeting the vascular endothelial growth factor pathway prolong the 
progression-free survival of patients with advanced RCC [29, 30]. Based on these, the postopera-
tive application of antiangiogenic medicine for patients with high-relapse risk RCC will play a 
positive role. Three randomized controlled trials, currently, have reported the outcomes of adopt-
ing targeted therapy for high-recurrence risk RCC. Although a study found that sunitinib treat-
ment 1-year postoperatively prolonged relapse-free survival for 1–2 years. Two other studies did 
not find a survival benefit [31–33]. Therefore, the European Association of Urological Surgeons 
does not recommend targeted drugs for postoperative RCC with high risk of relapse [34].
For patients with non-metastatic RCC and tumor thrombus, a cohort study designed by the 
Chinese PLA General Hospital analyzed the efficacy and safety of the postoperative adminis-
tration of sorafenib or sunitinib. The results showed that no survival benefit was observed for 
patients with tumor thrombus or IVC tumor thrombus who were administered postoperative 
adjuvant sorafenib or sunitinib [19].
6. Strategies and indications of IVC venography
Sufficient preoperative imaging data is requisite for successful thrombectomy. However, sev-
eral problems in the imaging diagnosis of IVC tumor thrombus still exist: Type-B ultrasound 
has difficulty in accurately diagnosing abnormal changes owing to numerous interferences. 
Magnetic resonance imaging (MRI) and computed tomography cannot effectively reflect the 
collateral circulation, and cannot define the degree of occlusion [35]. Therefore, more effective 
means are required to supplement these three routine examinations. IVC venography can 
observe the thrombus occlusion through the lateral position, which enables to maximize a 
rich data of tumor thrombus preoperatively and to make a more accurate surgical plan.
IVC venography has been widely used in the diagnosis of Budd-Chiari syndrome and other 
diseases [36]. There are still more applications in renal cancer with IVC tumor thrombus yet. 
Some studies reported that <15% of cases of patients with cancer thrombus would use IVC 
venography, and some researchers previously thought that the inspection might have false-
positive or false-negative results. Meanwhile, there is a risk of emboli-induced pulmonary 
embolism or tumor embolus exfoliate diffusion. Therefore, performing IVC venography rou-
tinely is not recommended [37, 38].
However, with the improvement of radiographic technique in recent years, the safety of IVC 
venography has been observably improved, and this method may define the formation of 
collateral circulation of the vena cava and help develop a thrombectomy strategy, which has 
unique diagnostic advantages. Hence, conducting a new study for IVC venography is neces-
sary. Based on our experience, we speculate that the following patients may be a candidate 
for IVC venography: (1) RCC with IVC tumor thrombus; (2) clearance of the tumor thrombus 
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plane; (3) definition of the degree of occlusion; (4) existence of collateral circulation, which 
may affect intraoperative vascular resection; (5) detection of the variation of the communi-
cating branches of vena cava, such as the variation communicating between IVC and vena 
azygos, which might interfere with the surgery.
7. Indications and strategies of intraoperative IVC interruption
With regard to dealing with the IVC intraoperatively is one of the difficulties of IVC throm-
bectomy. There necessity of reconstruction after IVC resection is still controversial.
Indications for vena caval interruption include invasion of the venous walls, severe adhesion of 
the tumor to the vascular endothelium, complete occlusion of the vena cava, and the presence of 
distal thrombus [21, 39, 40]. In addition, the texture of the cancer thrombus is one of the influenc-
ing factors. With regard to preoperative imaging, the IVC in line with the indications of interrup-
tion and accompanied by sufficient collateral circulation, meanwhile, without serious cardiac, 
hepatic, and renal insufficiencies can be completely cut off. IVC venography and intraoperative 
ultrasound can help determine the disjointed lumina, which enables protection of the estab-
lished collateral circulation trunk. IVC interruptions include complete and partial vena caval 
resections with reconstruction. Based on our experience, for right tumors, the height of the tumor 
thrombus, which is below the secondary hepatic portal, linear cutters are used to successively 
cut off the proximal, distal, and left renal veins of the tumor thrombus (Figure 1I). With regard 
to right tumor thrombus above the secondary hepatic portal, or left tumor thrombus above the 
level of the right renal vein and combined with distal thrombus, the vena cava can be resected 
partially. Methods for right thrombectomy include cutting off the lumina of the IVC below the 
secondary hepatic portal and reconstructing the lumina of the IVC above the secondary hepatic 
portal. The left thrombectomy procedure is resecting the lumina of the IVC below the level of 
the right renal vein and reconstructing the lumina of the IVC above the level of the renal vein.
Meanwhile, IVC interruption is safe and feasible during vena caval thrombectomy [39, 40], 
and the establishment of collateral circulation can avoid severe hemodynamic disorders. 
Different strategies of interruption ought to be generated preoperatively based on the height 
of tumor thrombus, tumor side, degree of vena caval obstruction and invasion, and establish-
ment of collateral circulation.
8. IVC tumor thrombus with thrombosis and treatment 
recommendations
Vena cava tumor thrombus with thrombosis is common. The prevalence of thrombosis gath-
ered by the Urological Department of Chinese PLA General Hospital is 19.2%. Thrombosis, at 
the same time, is not found within the renal venous tumor thrombus; all thrombosis occurred 
in the vena cava tumor thrombus. Among them, vena caval thrombi were all located on the 
right, the thrombus was located in the distal end of the tumor thrombus, and the distal throm-
bus could reach the bifurcation of the iliac vessel. Preoperative MRI can help determine the 
location and length of the thrombus.
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Preoperative anticoagulation therapy is recommended for patients with thrombosis, and 
medication should be administered from the diagnosis of tumor thrombus and thrombus. 
Low-molecular heparin is recommended for anticoagulation therapy, withdrawing drugs 
24 h preoperatively, maintaining the international normalized ratio of 2–3, and anticoagula-
tion therapy is continued for 48 h postoperatively and maintained for 6 months, except for the 
following: patients with tumor or tumor thrombus who did not undergo complete resection; 
those with metastasis; needs for systemic treatment; and patients with pulmonary embo-
lism. Pre- and postoperative placement of the vena cava stent is not recommended only if the 
patient has pulmonary embolism and contraindications of anticoagulation therapy [41, 42]. 
Preoperative imaging examinations are required for patients with extensive thrombosis at 
the distal end of the tumor thrombus [43]. IVC interruption is recommended, which prevents 
embolization caused by thrombus shedding, for patients who meet the indications and pos-
sess sufficient collateral circulation.
9. Other developments and issues
Besides the previously mentioned issues, some problems need to be solved in the field of RCC 
with tumor thrombus. First, whether the tumor thrombus is invading the venous walls is an 
important issue in diagnosis and treatment process to decide on the preoperative surgical 
strategies. Furthermore, it may also relate to postoperative survival. However, because the 
diagnostic criteria of imaging and pathology are currently insufficient, further studies should 
be conducted.
Second, the survival of patients with RCC and venous thrombus postoperatively was signifi-
cantly worse than those with localized RCC, particularly in patients with preoperative distant 
metastases. For IVC tumor thrombus, particularly patients with level III–IV tumor thrombus, 
the perioperative risk and mortality are higher. At the same time, although some patients com-
pleted the radical resection of tumor, survival after surgery is still less than 6 months. Therefore, 
for patients with high surgical risk or short life expectancy, the necessity for surgery deserves 
further discussions. The prognosis of patients with RCC and venous tumor thrombus, at pres-
ent, lacks the preoperative predicting models particularly related to imaging features. The study 
of preoperative imaging characteristics of tumor thrombus and biological behavior of the tumor 
and the prognosis of patients may provide some guidance for preoperative choice of treatment.
Augmented reality (AR) is a real-time technology to calculate the location and angle of the 
camera images and add corresponding images. The goal of this technology is to set the vir-
tual world in the real world and interact with it on screen [44]. Based on individual anatomy, 
the AR and computer system have been used in partial nephrectomy as a new technology in 
vivo and in vitro [45–47]. To overcome the problem of soft tissue and organ shift, Teber and 
colleagues reported a new navigation approach added to endoscope that was used in laparo-
scopic partial nephrectomy [47]. The study showed that the new AR tracking system proved 
to be effective, with a reasonable margin of error and a time to match each other. In addition, 
combining pre- or intraoperative imaging features with real-time endoscopy will simplify 
and increase the accuracy of laparoscopic surgery [47]. Thus, AR combined with three- 
dimensional vision has a great application value in robotic surgery in the future.
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Finally, although RCC invades the venous system to form tumor thrombus, the tissue com-
ponents between the primary tumor of the kidney and the tumor thrombus has a large differ-
ence. Meanwhile, heterogeneity exists in primary RCC and tumor thrombus, which may be 
the reason why primary tumor and tumor thrombus response to preoperative targeted ther-
apy was asynchronous, and drugs among different patients respond differently. Therefore, 
the research of heterogeneity between primary RCC and venous tumor thrombus may find a 
more effective therapeutic target and drug for the reduction of tumor thrombus level, which 
can provide the basis for selecting appropriate patients for neoadjuvant targeted therapy 
preoperatively.
10. Future perspectives
Open IVCTE is still a standard surgery for RCC with IVC thrombus. With the development 
of laparoscopy and robotic technology in recent years, the safety and feasibility of robot-
assisted laparoscopic IVC thrombectomy have been investigated at several centers. Those 
successful experiences mark that such surgery tends to enter the era of mini-traumatic 
surgery. Considering the complexity of the patient and the high complication rates, multi-
disciplinary cooperation and detailed preoperative assessment will play an important role 
in surgical decisions in future. Some new or mature techniques will also provide a basis for 
the surgical strategies, including artificial blood vessel, augmented reality, transesopha-
geal echocardiography, IVC venography, and so on. From a safety perspective, IVCTE is 
still a challenging technology. Only a hospital with skilled laparoscopic and mature surgi-
cal team is recommended. Preoperative TMT is expected to shrink the IVC thrombus and 
reduce the complexity of the surgery. However, prospective investigations are required in 
the future.
11. Conclusions
RCC tends to invade the venous system and form venous tumor thrombus in 4–10% of 
patients. Surgical treatment is the standard therapy for these patients; however, postopera-
tive complications include hemorrhage, thrombotic shedding, and other risks. Because of 
the huge population and relatively backward treatment concepts, the proportion and num-
ber of patients with advanced RCC in China are significantly higher than those in devel-
oped countries, such as Europe and the United States. With regard to patients with RCC 
and tumor thrombus, the strategies for diagnosis and treatment are mostly based on open 
surgery. Several clinic-related strategies are no longer suitable for current laparoscopic and 
robot-assisted mini-traumatic surgeries owing to the development of surgical techniques and 
improvement of auxiliary equipment. With regard to the tumor thrombus, a series of retro-
spective and prospective studies are needed to be conducted, which would enable to solve 
some difficulties and issues in the course of diagnosis and treatment, to improve the clinical 
strategies of diagnosis and treatment of patients with RCC and tumor thrombus ulteriorly, 
and to provide our clinical work with more powerful reference and basis.
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